View point. Bisphosphonates, osteoporosis and cardiovascular diseases

[No abstract available]

Авторы
Kartikey K.1 , Singh G.1 , Singh R.B. 1 , Al-Bawareed O.A. 2 , Mojto V.3 , Chibisov S. 4 , Kharlitskaya E. 5 , Abramova M. 6 , Blagonravov M. 7
Редакторы
-
Журнал
Издательство
-
Номер выпуска
3
Язык
Английский
Страницы
229-234
Статус
Опубликовано
Подразделение
-
DOI
-
Номер
-
Том
10
Год
2018
Организации
  • 1 Halberg Hospital and research Institute, Moradabad, India
  • 2 Department of Normal Physiology, People’s Friendship University of Russia, Moscow, Russian Federation
  • 3 Faculty of Medicine, Comenius University, Bratislava, Slovakia
  • 4 Department of Pathology and Pathophysiology, People’s Friendship University of Russia, Moscow, Russian Federation
  • 5 Faculty of Veterinary Sciences, People’s Friendship University of Russia, Moscow, Russian Federation
  • 6 Department of Anatomy, People’s Friendship University of Russia, Moscow, Russian Federation
  • 7 Department of Pathophysiology, RUDN, Moscow, Russian Federation
Ключевые слова
alendronic acid; bisphosphonic acid derivative; C reactive protein; cytochrome P450 1A1; denosumab; farnesyl trans transferase; hydroxymethylglutaryl coenzyme A reductase; omega 3 fatty acid; romosozumab; ubidecarenone; zoledronic acid; Article; bone density; bone mass; bone pain; bone remodeling; bone turnover; cardiovascular disease; cerebrovascular accident; femur fracture; femur intertrochanteric fracture; femur subtrochanteric fracture; fragility fracture; functional magnetic resonance imaging; gene mutation; heart infarction; heart protection; hip fracture; human; inflammation; jaw osteonecrosis; osteolysis; osteoporosis; oxidative stress; patient compliance; spine fracture; whole exome sequencing
Дата создания
19.07.2019
Дата изменения
19.07.2019
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/38348/